Banque Transatlantique SA Takes $855,000 Position in United Therapeutics Corporation $UTHR

Key Points

• Banque Transatlantique SA acquired a new position in United Therapeutics Corporation by purchasing 3,000 shares valued at approximately $855,000 during the first quarter.
• Several institutional investors have also adjusted their stakes, with Vanguard Group Inc. now owning over 4.4 million shares, reflecting ongoing investor interest in the biotechnology firm.
• United Therapeutics missed analysts' expectations in its latest quarterly earnings, reporting a net revenue of $798.60 million compared to an anticipated $802.13 million.

Banque Transatlantique SA acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 3,000 shares of the biotechnology company's stock, valued at approximately $855,000.

A number of other large investors have also made changes to their positions in UTHR. SVB Wealth LLC bought a new stake in United Therapeutics in the first quarter valued at about $32,000. Dunhill Financial LLC increased its stake in United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares during the period. Sound Income Strategies LLC bought a new stake in United Therapeutics in the first quarter valued at about $49,000. Brooklyn Investment Group increased its stake in United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 98 shares during the period. Finally, WPG Advisers LLC bought a new stake in United Therapeutics in the first quarter valued at about $60,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on UTHR shares. Wells Fargo & Company upped their target price on shares of United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research note on Wednesday. Jefferies Financial Group upped their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. HC Wainwright upped their price objective on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research note on Friday. JPMorgan Chase & Co. decreased their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 8th. Finally, Morgan Stanley decreased their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $429.62.

Insider Buying and Selling

In other news, Director Richard Giltner sold 3,036 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director owned 19,384 shares of the company's stock, valued at $5,613,606.40. This represents a 13.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the completion of the sale, the executive vice president owned 36,781 shares in the company, valued at approximately $10,297,208.76. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 118,181 shares of company stock worth $39,441,679. Company insiders own 10.30% of the company's stock.

United Therapeutics Price Performance

Shares of UTHR stock traded up $20.05 during trading hours on Friday, reaching $400.52. 924,693 shares of the company were exchanged, compared to its average volume of 848,265. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $436.95. The stock's fifty day moving average is $307.69 and its two-hundred day moving average is $305.80. The company has a market cap of $18.07 billion, a price-to-earnings ratio of 15.63, a P/E/G ratio of 6.08 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same quarter in the previous year, the company posted $5.85 earnings per share. United Therapeutics's revenue for the quarter was up 11.7% on a year-over-year basis. On average, research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.